SRSF2 and myelodysplastic syndrome: Meanwhile, the most common molecular event in the MDS patient cohort was a TET2 (77.4%) mutation, followed by ASXL1 (22.6%), U2AF1 (19.4%), NRAS (7.5%), TP53 (5.4%), SF3B1 (5.4%), DNMT3A (5.4%), CEBPA (5.4%) and SRSF2 (5.4%) mutations (Table 3).